Rituximab and Hyaluronidase Human
Sponsors
ECOG-ACRIN Cancer Research Group, Emory University, Fred Hutchinson Cancer Center, Thomas Jefferson University, Academic and Community Cancer Research United
Conditions
Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaBurkitt LymphomaClassic Follicular LymphomaCutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVDiffuse Large B-Cell Lymphoma
Phase 1
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
TerminatedNCT03864419
Start: 2019-10-24End: 2023-07-26Updated: 2024-01-03
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Active, not recruitingNCT04447716
Start: 2020-10-16End: 2027-04-30Updated: 2025-09-15
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Active, not recruitingNCT05455697
Start: 2023-01-26End: 2027-01-07Updated: 2026-06-22
Phase 2
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Active, not recruitingNCT03719131
Start: 2019-06-05End: 2026-06-30Updated: 2025-04-22
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Active, not recruitingNCT04626791
Start: 2021-08-03End: 2028-08-03Updated: 2026-08-25
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
TerminatedNCT04659044
Start: 2021-04-01End: 2024-03-29Updated: 2024-09-19
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Active, not recruitingNCT04799275
Start: 2021-05-20End: 2027-03-01Target: 422Updated: 2026-07-08
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
RecruitingNCT05886036
Start: 2024-01-23End: 2026-10-31Target: 70Updated: 2026-08-31
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Not yet recruitingNCT07724457
Start: 2026-10-30End: 2033-11-01Target: 271Updated: 2026-08-19
Phase 3
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Active, not recruitingNCT03267433
Start: 2017-11-27End: 2027-01-31Target: 689Updated: 2026-09-14
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Active, not recruitingNCT04759586
Start: 2021-10-05End: 2026-12-31Target: 244Updated: 2026-09-10
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
RecruitingNCT06337318
Start: 2024-10-23End: 2032-03-31Target: 600Updated: 2026-09-18
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
Not yet recruitingNCT07220187
Start: 2026-08-31End: 2036-10-01Target: 102Updated: 2026-06-11